Skip to main content

Research Repository

Advanced Search

Outputs (2)

Assessing emotional functioning with increased power: relative validity of a customized EORTC short form in the International ACTION Trial (2018)
Journal Article
Jabbarian, L. J., Groenvold, M., Petersen, M. A., Christensen, C. A., Deliens, L., van der Heide, A., …Korfage, I. J. (2019). Assessing emotional functioning with increased power: relative validity of a customized EORTC short form in the International ACTION Trial. Value in Health, 22(1), 92-98. https://doi.org/10.1016/j.jval.2018.07.002

Objectives

There is a need to improve the assessment of emotional functioning (EF). In the international Advance Care Planning: an Innovative Palliative Care Intervention to Improve Quality of Life in Cancer Patients - a Multi-Centre Cluster Rando... Read More about Assessing emotional functioning with increased power: relative validity of a customized EORTC short form in the International ACTION Trial.

A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up (2012)
Journal Article
Johnston, S. J., Kenny, F. S., Syed, B. M., Robertson, J. F. R., Pinder, S. E., Winterbottom, L., …Cheung, K. L. (2012). A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up. Annals of Oncology, 23(9), 2296-2300. https://doi.org/10.1093/annonc/mdr630

Background
Long-term analysis of a randomised trial in Nottingham comparing tamoxifen versus surgery as initial treatment demonstrated that in oestrogen receptor (ER)-unselected cases, surgery achieved better local control, with no difference in ove... Read More about A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up.